Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway

Int Immunopharmacol
June 2020
https://pubmed.ncbi.nlm.nih.gov/32171145/?from_single_result=32171145&expanded_search_query=32171145

Bernard Bihari, MD: Low-Dose Naltrexone for normalizing immune system function

Altern Ther Health Med
05 November 2013
http://todayspractitioner.com/wp-content/uploads/2013/10/Bernard-Bihari-MD-Low-dose-Naltrexone-for-Normalizing-Immune-System-Function-athm_19_2_bihari_56_65.pdf

Low-dose Naltrexone Targets the Opioid Growth Factor-Opioid Growth Factor Receptor Pathway to Inhibit Cell Proliferation: Mechanistic Evidence From a Tissue

Exp Biol Med (Maywood)
September 2011
https://pubmed.ncbi.nlm.nih.gov/21807817/

The Uses of Low-Dose Naltrexone in Clinical Practice

BMJ Case Reports
January 2018
https://www.researchgate.net/publication/328997819_Issue_4_The_Uses_of_Low-Dose_Naltrexone_in_Clinical_Practice

Off-label, Low-Dose Naltrexone for Refractory Chronic Low Back Pain

Pain Med
May 2014
https://europepmc.org/article/med/24967470

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis

BMC Medicine
15 January  2019
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1242-0

Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo

Int Immunopharmacol
September 2020
https://pubmed.ncbi.nlm.nih.gov/32585612/

Dr. Armin Schwarzbach, Infections in Cancer and Autoimmune Disorders. Presented by Markus Berger.

Mark Mandel, PharmD - LDN and Pets (2017 Conference) (LDN, low dose naltrexone)

Albeit a brief ten minute presentation, Dr Mandel proves to demonstrate how Low Dose Naltrexone (LDN) can be effective in treating inflammatory conditions in not only humans but also dogs and other pets.

Dana Flavin, MD - Reversing Cancer with Biochemistry (2018 Conference) (LDN, low dose naltrexone)

Dr Dana Flavin shares her presentation on Reversing Cancer at the LDN 2018 Conference.